Apologies if this has been posted before, but here’s the pastiest research from Edison Investments dated 25th September 2018.
https://www.edisoninvestmentresearch.com/?ACT=18&ID=22112&LANG=
If Fluence can deliver on its H218e target, its shares could re-rate sharply. Its membrane-aerated biofilm reactor (MABR) technology provides a competitive advantage in the growing market for decentralised water treatment. We see the ramp in sales here transforming its scale, revenue visibility and profitability by FY20e. The shares currently trade at a 28% discount to peers’ FY20 EV/EBITDA and a DCF approach, which assumes delivery in H2 and beyond, suggests value up to A$0.85 per share.
Apologies if this has been posted before, but here’s the...
-
- There are more pages in this discussion • 123 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add FLC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.010(9.09%) |
Mkt cap ! $129.7M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 12.5¢ | 11.0¢ | $43.08K | 370.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 75675 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 518962 | 4 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| FLC (ASX) Chart |